Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase I/II Study of Regorafenib Plus Avelumab in Solid Tumors

Next Previous
Trial Profile

A Phase I/II Study of Regorafenib Plus Avelumab in Solid Tumors

Status: Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 16 Jan 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Avelumab (Primary) ; Regorafenib (Primary)
  • Indications Adenocarcinoma; Biliary cancer; Carcinoma; Cholangiocarcinoma; Colorectal cancer; Gastric cancer; Gastrointestinal cancer; Gastrointestinal stromal tumours; Leiomyosarcoma; Liver cancer; Malignant-mesothelioma; Neuroendocrine tumours; Non-small cell lung cancer; Oesophageal cancer; Pancreatic cancer; Renal cell carcinoma; Soft tissue sarcoma; Solid tumours; Squamous cell cancer; Synovial sarcoma; Thyroid cancer; Triple negative breast cancer; Urogenital cancer
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms REGOMUNE

Most Recent Events

  • 05 Sep 2024 According to Bayer media release, results of the radioiodine-refractory differentiated thyroid cancer (RR-DTC) will be presented at the European Society for Medical Oncology (ESMO) Congress, taking place in Barcelona, Spain, from September 13-17, 2024.
  • 04 Jun 2024 Results (n=49) assessing synergistic effect of anti-angiogenesis and PD-1 blockade in altering the microenvironment of cold STS, potentially enhancing immune response and therapeutic efficacy presented at the 60th Annual Meeting of the American Society of Clinical Oncology
  • 10 Apr 2024 Results (n=38; Between January 2021 and July 2022)of study employing mTLS as a biomarker for patient selection for treatment with an immune checkpoint inhibitor-based regimen presented at the 115th Annual Meeting of the American Association for Cancer Research.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top